BioSpace News Archive

On December 17th, Health Canada formally indicated that they have found “Zopiclone impurity 22" in some batches of the U-Dream product.

Eureka 93 Inc. (CSE: ERKA, “Eureka93”) announced today that the current Board of Directors, after having reviewed strategic alternatives, approved a partial restructuring of its debt by executing a partial payment transaction for discharge of a material secured debt obligation.

LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Clinical Innovations for an enterprise value of $525 million.

Clinical Innovations, one of the largest medical device companies dedicated to labor and delivery and neonatal intensive care, has signed a definitive agreement to be acquired by LABORIE Medical Technologies for an enterprise value of $525M.

Monopar Therapeutics Inc. today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 166,666 shares of common stock

Health Canada is advising consumers that it has seized three unauthorized eye drop products from two Floy Beauty stores in Toronto, Ontario, because they may pose serious health risks.

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide assistance to patients who are living with hypercholesterolemia.

Rx-360 is pleased to announce their 2020 Board of Directors

The EQT Mid Market US fund and the EQT Mid Market Asia III fund (jointly “EQT”) have entered into an agreement to sell Clinical Innovations (the “Company”) to LABORIE Medical Technologies (“LABORIE”) for an Enterprise Value of USD 525m

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.